Aim: To investigate the effects of the cardiotonic steroid, ouabain, on cardiac differentiation of murine embyronic stem cells (mESCs). Methods: Cardiac differentiation of murine ESCs was enhanced by standard hanging drop method in the presence of ouabain (20 µmol/L) for 7 d. The dissociated ES derived cardiomyocytes were examined by flow cytometry, RT-PCR and confocal calcium imaging. Results: Compared with control, mESCs treated with ouabain (20 µmol/L) yielded a significantly higher percentage of cardiomyocytes, and significantly increased expression of a panel of cardiac markers including Nkx 2.5, α-MHC, and β-MHC. The α1 and 2-isoforms Na + /K + -ATPase, on which ouabain acted, were also increased in mESCs during differentiation. Among the three MAPKs involved in the cardiac hypertrophy pathway, ouabain enhanced ERK1/2 activation. Blockage of the Erk1/2 pathway by U0126 (10 µmol/L) inhibited cardiac differentiation while ouabain (20 µmol/L) rescued the effect. Interestingly, the expression of calcium handling proteins, including ryanodine receptor (RyR2) and sacroplasmic recticulum Ca 2+ ATPase (SERCA2a) was also upregulated in ouabain-treated mESCs. ESC-derived cardiomyocyes (CM) treated with ouabain appeared to have more mature calcium handling. As demonstrated by confocal Ca 2+ imaging, cardiomyocytes isolated from ouabain-treated mESCs exhibited higher maximum upstroke velocity (P<0.01) and maximum decay velocity (P<0.05), as well as a higher amplitude of caffeine induced Ca 2+ transient (P<0.05), suggesting more mature sarcoplasmic reticulum (SR). Conclusion: Ouabain induces cardiac differentiation and maturation of mESC-derived cardiomyocytes via activation of Erk1/2 and more mature SR for calcium handling.
Introduction
Embryonic stem cells (ESCs) have the ability to self-renew and differentiate into virtually all cell types of the three embryonic germ layers including cardiomyocytes. They thus represent an unlimited ex vivo cell source for cardiac regenerative therapy [1] [2] [3] [4] as well as an ideal in vitro model to investigate complex developmental processes. Spontaneous differentiation of ESCs towards cardiac lineage is generally poor [1, 5, 6] . To date, protocols have exploited transcription factors involved in embryonic heart development to direct ESC differentiation into cardiomyocytes [5] [6] [7] [8] . In contrast, transcription pathways crucially involved in post-natal hypertrophic growth of cardiomyocytes have not been investigated to improve the efficacy of cardiac differentiation of ESCs.
The cardiotonic glycoside ouabain is a specific inhibitor of the ubiquitous Na + /K + -ATPase that is responsible for the active transport of Na + and K + across the plasma membrane of most animal cells. In adult cardiomyocytes, Na + /K + -ATPase inhibition results in a modest increase in intracellular Na + , sufficient to affect the sarcolemmal Na + /Ca 2+ exchange and cardiac contractility [9] [10] [11] . Alterations in concentrations of endogenous cardiotonic glycosides have been reported in various human conditions such as essential hypertension [12] , asymptomatic left ventricular dysfunction [13] and dilated cardiomyopathy [14] . In experimental models, cardiotonic glycoside has cardioprotective effects against ischemia not associated Ouabain facilitates cardiac differentiation of mouse embryonic stem cells through ERK1/2 pathway www.chinaphar.com Lee YK et al Acta Pharmacologica Sinica npg with Na + /K + -ATPase inhibition [15, 16] . They also cause transcriptional regulation of several cardiac-growth related genes resulting in hypertrophy of adult cardiomyocytes [17] . Extensive subsequent studies of various cell types have revealed that binding of cardiotonic glycosides to Na + /K + -ATPase in fact activates multiple pathways including cytoplasmic tyrosine kinase Src/epidermal growth factor receptor (EGFR) [18] , phosphatidylinositol 3-kinase (PI3K)-Akt [19] , phospholipase C kinase, and increased mitochondrial production of reactive oxygen species [20] . The downstream signaling pathway nonetheless appears to be cell-type specific. A previous report demonstrated the functional expression of Na + /K + -ATPase in undifferentiated ESCs as well as ESC-derived cardiomyocytes [5] although the effect of ouabain on cardiac differentiation and maturation of ESCs remains unclear. The aims of the present study were thus to determine whether ouabain, the prototypic Na + /K + -ATPase inhibitor and potent hypertrophic stimulus of adult cardiomyocytes, affects cardiac differentiation and maturity of ESCs. In order to validate the cardiac differentiation of ESCs, we quantified the number of troponinpositive cells using flow cytometry and the expression of a panel of cardiac specific markers in differentiated ESCs. We also studied the effects of ouabain on the extracellular signalregulated kinase (ERK), c-Jun NH 2 -terminal protein kinase (JNK), and p38 mitogen activated protein kinase (MAPK) during cardiac differentiation of ESCs. Treatment with a specific MAPK inhibitor would be useful to investigate the specific role of MAPK in cardiac differention. In addition, the maturity of calcium handling properties of differentiated ESCs was assessed using confocal calcium imaging.
Materials and methods
Murine embryonic stem cell culture and in vitro cardiac differen tiation Murine (m) ES cell-line D3 (CRL-1934, American Type Culture Collection, Manassas, VA) was used and cultured as previously described [21] . Briefly, undifferentiated mESCs were cultured on an irradiation-inactivated monolayer of mouse embryonic fibroblast feeders in Dulbecco's modified Eagle's minimal essential medium (DMEM, Gibco BRL, Karlsruhe, Germany), supplemented with 15% fetal bovine serum (FBS, Gibco BRL, Karlsruhe, Germany), 0.1 mmol/L mercaptoethanol (Sigma-Aldrich, St Louis, MO), non-essential amino acids (stock solution diluted 1:100; Hyclone, Logan, UT) and 1000 U/mL of recombinant mouse leukemia inhibitory factor (LIF) (Chemicon, Hofheim, Germany). To induce cardiac differentiation, embryoid bodies (EBs) were generated from hanging drops of approximately 800 mESCs in 20 μl of culture medium in the absence of leukemia inhibitory factor and feeder cells for two days and then grown in suspension or five more days [21] . 
Cell viability
Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-y)-2,5-diphenyl-tetrazolium bromide (MTT) staining method described by Mosmann T and Hansen in a 96-well microtiter plate [22] . This method is based on the ability of viable, but not dead cells, to convert MTT to a blue colored formazan. Stock MTT solution (5 mg/mL) was prepared in PBS. Ten EBs were plated onto each 96-well coated plate with 0.1% gelatin following 5-day suspension and differentiation medium served as control. At the end of incubation, 20 µL of MTT solution was added to each well containing 180 µL medium with various concentrations of ouabain. Following 4 h incubation at 37 °C, dark crystals formed and the reaction was stopped by adding 100 µL of DMSO. The optical density (OD) of each well was read on a Bio-Rad 550 Microplate Reader (Bio-Rad Laboratories, Hercules, CA) at 570 nm. The viability values obtained in the presence of various dosages of ouabain were subsequently normalized against control values.
Isolation of beating mESCderived cardiomyocytes
The beating outgrowths were microsurgically dissected with a glass knife from D3 mESC-derived 7-day differentiated EBs, and incubated in collagenase B (1 mg/mL) with DNase I (60 U/mL, Roche Applied Sciences Penzberg, Germany) at 37 °C for 30 min with occasional dispersion by pipetting up and down. Isolated cells were recovered in Kraftbrühe (KB) solution containing (mmol/L) 85 KCl, 30 K 2 HPO 4 , 5 MgSO 4 , 1 EGTA, 2 Na 2 -ATP, 5 pyruvic acid, 5 creatine, 20 taurine, and 20 D-glucose at room temperature for 1 h. The cells were subsequently plated on 0.1% gelatin coated glass cover slips in 24-well culture plates with corresponding differentiation medium. Calcium imaging of isolated cells or cell clusters was performed within 2 days; some of the cells were fixed in 4% paraformaldehyde for immunocytological staining at 4 °C.
Immunocytological staining
The 7-day differentiated EBs were microdissected and fixed with 2% paraformaldehyde for 20 min at 4 °C, followed by washing with wash buffer [DPBS with 0.1% Triton X-100 (Sigma-Aldrich, St Louis, MO)] once for 5 min. Cells were incubated overnight at 4 °C with anti-troponin-T (1:100, Lab Assessment of cardiac differentiation using reverse transcription polymerase chain reaction Total RNA from 7-day old EBs was extracted with Trizol ® reagent (Invitrogen, life technologies, Carlsbad, CA). Reverse transcription was then performed using 1 µg of total RNA in a final volume of 20 µL, using the QuantiTect ® reverse transcription kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Cardiac-specific genes, alpha isoforms of sodium-potassium ATPase and calcium handling proteins were compared in EBs in the presence or absence of ouabain with quantitative real-time polymerase chain reaction (qPCR). Primer sequence and annealing temperature are depicted in 
Results
Ouabain enhanced cardiac differentiation of mESCs The effect of ouabain on the viability of differentiating mESCs was determined by MTT assay at different concentrations of ouabain for 72 h. Ouabain was well tolerated even in relatively high concentrations in differentiating mESCs ( Figure  1A ). To assess whether ouabain treatment enhances cardiac differentiation of mESCs and to determine the optimal range ouabain dosage in enhancing cardiac differentiation, flow cytometry to determine the percentage of cardiomyocytes as identified by troponin-T positive cells was performed. As depicted in Figure 1B and 1C, the optimal dosage of ouabain to enhance cardiac differentiation of mESC was about 10 µmol/L ( Figure 1A and 1B). Taken together with the viability test, ouabain at concentration of 20 µmol/L was selected for subsequent experiments. Cardiac differentiation of undifferentiated mESCs was assessed by the percentage of spontaneous beating EBs under the microscope and troponin-T positive cells using flow cytometry at d 7. In this study, spontaneous beating outgrowths from EBs were first observed on d 2 in both ouabaintreated EBs and controls (12.5%), and progressively increased until reaching a plateau at d 9. The administration of ouabain resulted in a higher percentage of spontaneous beating outgrowths of EBs compared with controls from d 6 to d 9 ( Figure  1B) . Standard, counting of beating outgrowths from EBs is nevertheless a very crude measurement of the efficiency of cardiac differentiation [4] . The percentage of cardiomyocytes was consistently significantly higher in the ouabain group (9.50%±1.82% vs 2.90%±0.20%; n=3, P<0.05). Figure 2 shows the immunocytochemical pattern of cardiacspecific cytoskeletal proteins including troponin-T in mESCderived cardiomyocytes. Cardiomyocytes derived from controls showed a homogeneous distribution of troponin-T protein resembling early stage cardiomyocytes (Figure 2 ) [23] ; cardiomyocytes from the ouabain group demonstrated striations of the myofilament specific protein indicating sarcomere development, a marker for late-stage cardiomyocytes.
Ouabain-induced expression of cardiac specific genes
The effect of ouabain on the expression of cardiac marker genes in EBs was examined by quantitative RT-PCR. The expression of cardiac transcription factors, including Nkx2.5, significantly increased (almost double) in the ouabain group on d 7 (n=3, P<0.05), but not GATA-4 and GATA-6, the transcription factors common for mesoderm and endoderm ( Figure 3A ). In addition, gene expression of sarcomeric muscle proteins (α-MHC and β−MHC) was increased in the ouabain group compared with the control (n=3; P<0.05 and www.nature.com/aps Lee YK et al Acta Pharmacologica Sinica npg P<0.01 respectively). Of note, the expression of α-MHC, the adult isoform of myosin heavy chain, was markedly up-regulated with ouabain treatment by about 3.5-fold ( Figure  3A) . The authenticity of increase α-MHC gene expression was confirmed with Western blot experiment ( Figure 3B ). As a potential target of ouabain, the expression kinetics of α subunit isoforms of Na + /K + ATPase in mESCs during differentiation was also investigated using RT-PCR. The mRNA of all three isoforms: α1, α2, and α3 subunits was detected in both undifferentiated mESCs and mESC-derived cardiomyocytes at 7-day differentiation; nonetheless α1 and 2 isoforms were the most responsive to ouabain treatment ( Figure 3C ). In addition, mRNA expression of a panel of calcium handling proteins, including RyR2 and SERCA2a, ( Figure 3D ) was upregulated in the ouabain group.
Ouabainenhanced calcium handling of cardiomyoyctes derived from mESCs
To investigate whether up-regulation of calcium handling proteins in cardiomyocytes from the ouabain group was associated with more mature calcium handling properties, spontaneous calcium oscillations in single cardiomyoyctes isolated from ouabain-treated EBs were characterized on d 7 using confocal laser microscopy and compared with that of the control. Consistent with the up-regulated calcium handling proteins, the ouabain group exhibited more mature calcium handling properties ( Figure 4A ). Specifically, cardiomyocytes from the ouabain group generated larger calcium transients Ouabain increases cardiac differentiation of mESCs by Erk1/2 activation Various MAPK-signaling cascades including ERK, c-JNK and p38 MAPK play important roles in cardiac hyper trophy [17, 24] and cardiac remodeling following myocardial infarction. In order to determine whether the enhanced cardiac differentiation on administration of ouabain is related to MAPKsignaling cascades involved in the hypertrophy pathway, phosphorylation of ERK, c-JNK, and p38 MAPK in ouabaintreated EBs was determined and compared with controls. On d 7, ouabain treatment resulted in a significant surge in phosphorylation of ERK1/2 ( Figure 6A) ; no significant difference between the ouabain group and control was found in phosphorylation of either JNK1/2 or p38 MAPK ( Figure  6B ). The MEK1/2 inhibitor U0126 suppressed ouabainactivated tyrosine phosphorylation of ERK1/2 ( Figure 7A ), indicating that ERK1/2 was likely activated by ouabain stimulation of MEK1/2 activity. To further study the effect of Erk1/2 activation on cardiac differentiation of mESCs, FACS experiments were performed by blocking the Erk1/2 pathway. Addition of the MEK1 inhibitor, U0126, which subsequently blocks MEK1/2, upstream of ERK1/2, suppressed the percentage of troponin-T positive cells to 0.53%±0.28% (n=3, P<0.01 compared with control) (Figure 7) while ouabain rescued the effect to control levels (n=3, P<0.05 compared with U0126).
Discussion
We evaluated the effects of ouabain on cardiac differentiation of mESCs. Our results demonstrate that ouabain promotes cardiogenesis and myofibrillogenesis of ESCs, and matures the calcium handling properties of cardiomyocytes derived there- [17, 24] and the documented functional expression of Na + /K + -ATPase in undifferentiated mESCs [5] , the potential procardiogenic effects of ouabain have not been explored. Binding of ouabain to Na + /K + -ATPase, in addition to the positive inotropic effect, also activates multiple MAPK pathways in a cell-type specific manner. Previous studies have suggested that MAPK activation may play a crucial role in mesoderm induction, which leads subsequently to cardiogenesis during embryonic development [25, 26] . Coordinated activation of the three major MAPKs involved in cardiac hypertrophy namely ERK1/2, JNK, and p38 MAPK, are essential to induce cardiac differentiation of P19 embryonic carcinomal cell line [27, 28] . In the present study, application of ouabain to undifferentiated mESCs resulted in a modest increase in the number of troponin-positive cells differentiated from mESCs. This was associated with increased expression of early cardiac specific transcription factors (Nkx2.5) and cardiac specific markers (α-MHC and β-MHC). Consistent with a previous study [29] , ERK1/2, JNK and p38 MAPK were endogenously activated in mESCs during differentiation. Only ERK1/2 though was significantly activated upon ouabain treatment. Since specific blocker for ERK1/2 is not available, U0126, an upstream MEK1/2 blocker, were used to study the pathway, of which ouabain induced cardiogenesis. Due to the non-specificity of MEK1/2 blocker, it is possible that other mechanisms independent of ERK1/2 activation may be involved in ouabain induced cardiac differentiation in mECSs. Nonetheless, the specific role of ouabain in Erk1/2 activation was well defined by the inhibitor experiment. Interestingly, various cytokines or growth factors, including cardiotrophin-1 [30] , VEGF [31] , and heregulin-β1 [8] , which promote cardiac differentiation of mESCs, also mediate via the [29] . Taken together, this evidence suggests that adult cardiac hypertrophic signals, particularly the MAPK pathway, may play a role in the cardiac differentiation in ESCs, and may be exploited to improve the efficiency of cardiac differentiation.
Another important hurdle for ESC-based cardiac therapies is the relative immature calcium handling properties of ESCderived cardiomyocytes [2, [32] [33] [34] . In adult cardiomyocytes, calcium enters the cell through L-type calcium channels during phase 2 of action potentials. This relative small calcium influx in turn triggers a large calcium release from the internal calcium store, SR through ryanodine receptors [35] . This process is known as calcium-induced calcium release (CICR), the primary mechanism that links electrical excitation and mechanical contraction in cardiomyocytes. During diastole, calcium is actively removed from cytosol, mainly through sarco/endoplasmic reticulum Ca 2+ -ATPase pump (SERCA), back into the SR and via Na + -Ca 2+ exchanger (NCX) out of cell [36] . mESC-derived cardiomyocytes are known to exhibit immature calcium dynamics: small cytosolic calcium transient amplitudes, slow rise and decay kinetics, and reduced calcium content of SR. This adversely affects excitation-contraction coupling [37] and is partly related to the relatively underdeveloped SR and partly to the developmental expression profiles of calcium handling proteins in mESC-derived cardiomyocytes.
In the present study, ouabain treatment favorably altered the calcium handling properties of mESC-derived cardiomyocytes including larger calcium transients, a faster rate of rise and decay of calcium transients, and thus resulted in a stronger contractile force. In addition, cardiomyoctyes isolated from ouabain-treated EBs also appeared to have a larger internal store of calcium as evidenced by larger amplitude of caffeinemediated calcium release. These changes could be related to the corresponding upregulation of key calcium handling proteins in cardiomyocytes isolated from ouabain-treated EBs. Specifically, the upregulated ryanodine receptor could result in the faster rate of calcium release, while the rate of calcium transient decay corresponds to the higher expression of SERCA in ouabain-treated cardiomyocytes. The enhanced intracellular calcium concentration due to Na + /K + -ATP inhibition nonetheless remains another plausible mechanism for such improvement.
Our results shed new light on the potential use of a hypertrophic stimulus on adult cardiomyocytes to enhance cardiac differentiation and maturation of ESC-CMs in vitro. Ouabaindriven cardiac differentiation of mESC-CMs is mediated by activation of Erk1/2 in the hypertrophy pathway. The relationship of the pathway with calcium handling in the cells was not identified. Nonetheless, our findings broaden knowledge of the differentiation processes of cultured ESCs, and may also contribute to the future development of step-cell based therapy for heart disease.
